Literature DB >> 9882712

Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II.

H S Speno1, R Luthi-Carter, W L Macias, S L Valentine, A R Joshi, J T Coyle.   

Abstract

Glutamate carboxypeptidase II (GCP II) catalyzes the extracellular hydrolysis of the neuromodulator N-acetyl-aspartylglutamate to N-acetyl-aspartate and glutamate. GCP II also hydrolyzes gamma-glutamyl bonds in folylpolyglutamate. The predicted amino acid sequence of GCP II displays similarities to aminopeptidases from Streptomyces griseus and Vibrio proteolyticus, whose crystal structures have been determined. These aminopeptidases are cocatalytic zinc metallopeptidases belonging to the peptidase family M28. Specific zinc and substrate ligands have been proposed in GCP II based on the amino acid sequence alignment to these M28 family members. In the present study, site-directed mutagenesis has been used to test the assignment of these putative ligands in human GCP II. Substitutions to the five putative zinc ligands resulted in severely reduced enzyme activity, although mutant protein was expressed as demonstrated by immunoblot analysis. In addition, substitutions of amino acids near the putative zinc ligands have identified other specific residues important for enzyme structure and/or function. Substitutions to putative substrate ligands were less perturbing, and increases in Km were observed for substitutions that introduced a large charge perturbation (e.g., Lys to Glu). The results from substitutions at the proposed zinc and substrate ligands are consistent with the assignment of these residues and suggest that GCP II has a three-dimensional structure similar to other members of the peptidase family M28.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882712     DOI: 10.1124/mol.55.1.179

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

Review 1.  NAAG, NMDA receptor and psychosis.

Authors:  Richard Bergeron; Joseph T Coyle
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Authors:  Mindy I Davis; Melanie J Bennett; Leonard M Thomas; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

4.  Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Authors:  Polly D Gregor; Jedd D Wolchok; Vandana Turaga; Jean-Baptiste Latouche; Michel Sadelain; Dean Bacich; Warren D W Heston; Alan N Houghton; Howard I Scher
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

Review 5.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Structural characterization of Zn(II)-, Co(II)-, and Mn(II)-loaded forms of the argE-encoded N-acetyl-L-ornithine deacetylase from Escherichia coli.

Authors:  Ye Tao; Jacob E Shokes; Wade C McGregor; Robert A Scott; Richard C Holz
Journal:  J Inorg Biochem       Date:  2012-02-14       Impact factor: 4.155

7.  Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family.

Authors:  Lisa Ann Lambert; Stacey L Mitchell
Journal:  J Mol Evol       Date:  2006-12-09       Impact factor: 2.395

8.  Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.

Authors:  Liqun Han; Jonathan D Picker; Laura R Schaevitz; Guochuan Tsai; Jiamin Feng; Zhichun Jiang; Hillary C Chu; Alo C Basu; Joanne Berger-Sweeney; Joseph T Coyle
Journal:  Synapse       Date:  2009-08       Impact factor: 2.562

9.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

10.  The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.

Authors:  Norbert Schülke; Olga A Varlamova; Gerald P Donovan; Dangshe Ma; Jason P Gardner; Donna M Morrissey; Robert R Arrigale; Cenchen Zhan; Amy J Chodera; Kenneth G Surowitz; Paul J Maddon; Warren D W Heston; William C Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.